MY201688A - Vaccine - Google Patents
VaccineInfo
- Publication number
- MY201688A MY201688A MYPI2017700715A MYPI2017700715A MY201688A MY 201688 A MY201688 A MY 201688A MY PI2017700715 A MYPI2017700715 A MY PI2017700715A MY PI2017700715 A MYPI2017700715 A MY PI2017700715A MY 201688 A MY201688 A MY 201688A
- Authority
- MY
- Malaysia
- Prior art keywords
- denv
- vaccine
- hbsag
- linked
- terminal
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 241000725619 Dengue virus Species 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Cartons (AREA)
- Packaging Of Annular Or Rod-Shaped Articles, Wearing Apparel, Cassettes, Or The Like (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2478DE2014 | 2014-09-01 | ||
| PCT/IB2015/056352 WO2016034974A1 (en) | 2014-09-01 | 2015-08-21 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY201688A true MY201688A (en) | 2024-03-13 |
Family
ID=55439184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2017700715A MY201688A (en) | 2014-09-01 | 2015-08-21 | Vaccine |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10189877B2 (enExample) |
| EP (2) | EP3188755B1 (enExample) |
| JP (3) | JP6983653B2 (enExample) |
| CN (1) | CN107074968B (enExample) |
| CA (1) | CA2959280C (enExample) |
| CY (1) | CY1123664T1 (enExample) |
| ES (1) | ES2821480T3 (enExample) |
| HR (1) | HRP20201523T1 (enExample) |
| HU (1) | HUE053284T2 (enExample) |
| LT (1) | LT3188755T (enExample) |
| MX (2) | MX385222B (enExample) |
| MY (1) | MY201688A (enExample) |
| PL (1) | PL3188755T3 (enExample) |
| PT (1) | PT3188755T (enExample) |
| RS (1) | RS61000B1 (enExample) |
| SI (1) | SI3188755T1 (enExample) |
| SM (1) | SMT202000589T1 (enExample) |
| WO (1) | WO2016034974A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2821480T3 (es) * | 2014-09-01 | 2021-04-26 | Int Centre For Genetic Engineering And Biotechnology | Vacuna |
| EP3621645A4 (en) * | 2017-05-10 | 2021-01-27 | University of Massachusetts | BIVALENT VACCINES AGAINST DENGUE / HEPATITIS B |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4766205A (en) * | 1985-11-13 | 1988-08-23 | Beatrice Companies, Inc. | Method for isolation of recombinant polypeptides in biologically active forms |
| JP3954643B2 (ja) * | 1991-11-16 | 2007-08-08 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | マラリア原虫由来のＣＳおよびＨＢｓＡＧ間のハイブリッド蛋白質 |
| FR2741077B1 (fr) * | 1995-11-14 | 1998-01-23 | Pasteur Institut | Vaccin polyvalent anti-dengue |
| WO2007034507A2 (en) * | 2005-09-20 | 2007-03-29 | International Centre For Genetic Engineering And Biotechnology | Tetravalent dengue specific domain iii based chimeric recombinant protein |
| WO2008152652A2 (en) * | 2007-06-12 | 2008-12-18 | International Centre For Genetic Engineering And Biotechnology | A dengue envelope domain iii-based tetravalent protein vaccine |
| WO2010043977A2 (en) * | 2008-10-13 | 2010-04-22 | Institute For Research In Biomedicine | Dengue virus neutralizing antibodies and uses thereof |
| CN101962411B (zh) * | 2009-07-24 | 2012-09-05 | 中国疾病预防控制中心病毒病预防控制所 | 登革病毒血清学早期诊断试剂 |
| CN102906266A (zh) * | 2010-05-21 | 2013-01-30 | 高等教育联邦系统-匹兹堡大学 | 登革病毒通用序列及其使用方法 |
| CN103193870B (zh) * | 2013-04-22 | 2014-10-22 | 中国人民解放军第三军医大学 | 一种登革病毒简并疫苗及其应用 |
| ES2821480T3 (es) * | 2014-09-01 | 2021-04-26 | Int Centre For Genetic Engineering And Biotechnology | Vacuna |
-
2015
- 2015-08-21 ES ES15775490T patent/ES2821480T3/es active Active
- 2015-08-21 US US15/506,379 patent/US10189877B2/en active Active
- 2015-08-21 MY MYPI2017700715A patent/MY201688A/en unknown
- 2015-08-21 MX MX2017002621A patent/MX385222B/es unknown
- 2015-08-21 LT LTEP15775490.4T patent/LT3188755T/lt unknown
- 2015-08-21 JP JP2017511582A patent/JP6983653B2/ja active Active
- 2015-08-21 SI SI201531356T patent/SI3188755T1/sl unknown
- 2015-08-21 PL PL15775490T patent/PL3188755T3/pl unknown
- 2015-08-21 SM SM20200589T patent/SMT202000589T1/it unknown
- 2015-08-21 CN CN201580046960.4A patent/CN107074968B/zh active Active
- 2015-08-21 PT PT157754904T patent/PT3188755T/pt unknown
- 2015-08-21 HU HUE15775490A patent/HUE053284T2/hu unknown
- 2015-08-21 WO PCT/IB2015/056352 patent/WO2016034974A1/en not_active Ceased
- 2015-08-21 EP EP15775490.4A patent/EP3188755B1/en active Active
- 2015-08-21 CA CA2959280A patent/CA2959280C/en active Active
- 2015-08-21 EP EP19215426.8A patent/EP3685852A1/en active Pending
- 2015-08-21 RS RS20201131A patent/RS61000B1/sr unknown
- 2015-08-21 HR HRP20201523TT patent/HRP20201523T1/hr unknown
-
2017
- 2017-02-27 MX MX2021006543A patent/MX2021006543A/es unknown
-
2018
- 2018-12-06 US US16/211,564 patent/US10815280B2/en active Active
-
2020
- 2020-06-03 JP JP2020096790A patent/JP6985458B2/ja active Active
- 2020-09-22 CY CY20201100890T patent/CY1123664T1/el unknown
- 2020-10-22 US US17/077,206 patent/US11945842B2/en active Active
-
2021
- 2021-11-25 JP JP2021191104A patent/JP7333373B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015286723B2 (en) | Influenza virus vaccines and uses thereof | |
| PT3137505T (pt) | Combinação de lenalidomida e construção polipeptídica e utilizações desta | |
| ZA201701851B (en) | Fmdv recombinant vaccines and uses thereof | |
| PH12016501873A1 (en) | Anti-influenza b virus hemagglutinin antibodies and methods of use | |
| SG11201606624WA (en) | Antibody moleules to dengue virus and uses thereof | |
| IN2014KN03063A (enExample) | ||
| MY181175A (en) | Therapeutic hpv16 vaccines | |
| PH12016502500B1 (en) | Influenza virus vaccines and uses thereof | |
| IL257986A (en) | Expression of recombinant proteins in Trichoplusia ni pupa | |
| IL259287A (en) | A charge-reversal n-terminal region of spider silk protein | |
| EA201691429A1 (ru) | МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp | |
| SG11201610731VA (en) | A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection | |
| EA201692552A1 (ru) | МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp | |
| IL249294A0 (en) | A preparation containing factor viii and von Willebrand factor peptides | |
| DK3146042T3 (da) | Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop | |
| MX380859B (es) | Nuevos derivados de cath2. | |
| LT3110837T (lt) | Tatk-cdkl5 sulieti baltymai, kompozicijos, sudėtys ir jų panaudojimas | |
| SG11201703366RA (en) | Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development | |
| MX2017008286A (es) | Nuevos metodos para el despliegue de peptidos ciclicos en particulas de bacteriofagos. | |
| WO2014152946A3 (en) | Polypeptides for treating and/or limiting influenza infection | |
| CY1123664T1 (el) | Εμβολιο | |
| SG10201913659SA (en) | Foxm1-derived peptide, and vaccine including same | |
| PH12018500986A1 (en) | Methods and compositions for dengue virus vaccines and diagnostics | |
| DK3178838T3 (da) | Koc1-afledt peptid og vaccine, der indbefatter dette | |
| LT3626729T (lt) | Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš hepatoceliulinę karcinomą (hck) ir kitų rūšių vėžį |